Group leader: This email address is being protected from spambots. You need JavaScript enabled to view it. (Professor, MD, Ph.D.)
Members: Ulrica Marklund (postdoc, Ph.D.), Linda Yrlid (postdoc, Ph.D.), Dubravka Eliasson (postdoc, Ph.D.), Ellen Marks (Ph.D. student), Peter Bergqvist (Ph.D. student), Johan Mattsson (Ph.D. student), Annemarie Hasselberg (Ph.D. student), Lena Ekman (technichian), Karin Schön (technichian) and Anneli Stensson (technichian).

We have pioneered the development of cholera toxin (CT) derived immmunomodulators and have acquired patents for a family of unique mucosal modulators and adjuvants, based on the CTA1-DD gene nlfusion protein. This molecule capitalizes on  the ADP-ribosylating function of the CT A1-subunit, which is expressed together with a dimer of fragment D from the Staph. aureus proteinA. The CTA1-DD has been found to target cells of the innate immune system with little reactogenic effect on the site of injection or administration. Thus, the CTA1-DD is a non-toxic enzyme-dependent highly efficacious adjuvant system for a wide range of immune responses including priming of CD4 T cells,  CTL and antibody responses. Enzymatically inactive mutants on the other hand are effective inducers of antigen-specific T cell tolerance and are currently exploited in various anti-inflammatory treatments. Moreover, we have developed novel formulations which incorporate CTA1-DD into immune stimulating complexes (ISCOMs). These adjuvant vectors have been found highly effective for a large number of candidate vaccines and currently feasibility studies with influenza virus, rota virus, tuberculosis, Helicobacter pylori and HIV-vaccines are ongoing. Clinical trials with the CTA1-DD adjuvant are planned for 2007 and GMP-material should be available by late 2006.
Other areas of intense research in the group include basic studies of  IgA B cell development in the gastro-intestinal tract, female genital tract T-cell immunity and infections caused by Chlamydia trachomatis,  or gastric infections with Helicobacter pylori and important role of CD4 effector T cells in the afflicted gastric mucosa.

Important publications:
Eriksson A, Schön K and Lycke N. (2004). The Cholera Toxin-Derived CTA1-DD Vaccine Adjuvant Administered Intranasally Does Not Cause Inflammation or Accumulate in the Nervous Tissues. J. Immunol. 173: 3310-3319

Akhiani A, Stensson A, Schön K and Lycke N. (2005). IgA antibodies impair resistance against Helicobacter pylori infection; studies on immune evasion in IL-10 deficient mice. J. Immunol., 174:8144-8153, 2005

Grdic D, Ekman L, Schön K, Lindgren K, Mattsson J, Magnusson K-E, Ricciardi-Castagnoli P and Lycke N. (2005). Splenic marginal zone dendritic cells mediate the cholera toxin adjuvant effect: dependence on the ADP-ribosyl transferase activity oth the holotoxin. J. Immunol., 175: 5192-5202

Helgeby A, Robson N, Donachie A, Beackock-Scharp H, Lövgren K, Mowat A and Lycke N. (2006). The combined CTA1-DD/ISCOM adjuvant vector promotes priming of mucosal and systemic immunity to incorporated antigens by specific targeting of B cells.  J Immunol. 176:3697-3706.